ReviewNature ecology & evolution2025
The current state, opportunities and challenges for upscaling private investment in biodiversity in Europe.
Review in Nature ecology & evolution, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A framework for unit-level biodiversity credit integrity and market-level governance.npj biodiversity · 2026Article
- Biodiversity isn't measured in tons: Making sense of nature in the context of sustainable agriculture.Ecological applications : a publication of the Ecological Society of America · 2026Review
- Five rules for scientifically credible nature markets.Nature ecology & evolution · 2026Review
- Grain fields in sea-landscapes.Ambio · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
European countries have committed to ambitious upscaling of privately funded nature conservation. We review the status and drivers of biodiversity finance in Europe. By implementing semistructured interviews with 25 biodiversity finance key informants and three focus groups across Europe, we explore opportunities and challenges for upscaling private investment in nature. Opportunities arise from macroeconomic and regulatory changes, along with various technological and financial innovations and growing professional experience. However, persistent barriers to upscaling include the ongoing lack of highly profitable investment opportunities and the multitude of risks facing investors, including political, ecological and reputational risks influencing supply and demand of investment opportunities. Public policy plays the foundational role in creating and hindering these mechanisms. Public policy can create nature markets and investment opportunities, meanwhile agricultural subsidies and poor coordination between public funding sources undermine the supply of return-seeking investment opportunities. Investors demand derisking investments from uncertainties; in part caused by political uncertainty. These markets require profound state intervention to enable upscaling whilst achieving positive ecological outcomes; private investment will probably not upscale without major public policy change and public investment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.